Ascletis Raises $100MM To Deploy Its U.S.-China Hybrid Drug Development Model
This article was originally published in PharmAsia News
In the latest and most ambitious attempt to create a new global pharma with one foot in China and one in the West, Ascletis Inc. has launched with a hybrid drug development model that has attracted $100 million in committed funding
You may also be interested in...
Chinese-U.S. hybrid MicuRx, founded by Vicuron veterans, has strong preclinical and Phase I data for a novel antibiotic targeting Gram-positive infections. Its cross-border approach will soon support two mid-stage trials.
China's life sciences industry is at a crossroads, and new commercial models are needed to drive future growth, but a disconnect between corporate strategies may derail execution.
U.S.-China hybrid Ascletis Inc. has reinforced ties between China and the U.S. under a memorandum of understanding signed July 16 with the Hangzhou Hi-Tech Industry Development Zone in Zhejiang Province, China, and The Hamner Institutes for Health Sciences in Research Triangle Park, North Carolina